← Back to Screener
ZOETIS INC. (ZTS)
Price$79.44
Value ScoreC
Growth ScoreC
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-45.95%
Price vs S&P 500 (4W)-4.08%
VGM Score46.38
Market Capitalization$32.53B
P/E Ratio (Annual)12.17x
Indicated Dividend Yield (Annual)1.64%
All Metrics
P/CF (Annual)11.20x
Book Value / Share (Quarterly)$7.69
P/TBV (Annual)23.77x
Indicated Dividend (Annual)$2.12
Revenue Growth (3Y)5.42%
Cash Flow / Share (Quarterly)$5.08
Payout Ratio (TTM)33.64%
Price vs S&P 500 (YTD)-45.02%
Gross Margin (TTM)71.82%
Net Profit Margin (TTM)27.79%
EPS (TTM)$6.04
10-Day Avg Trading Volume7.03M
EPS Excl Extra (TTM)$6.04
Revenue Growth (5Y)7.24%
EPS (Annual)$6.02
Dividend / Share (Annual)$2.04
ROI (Annual)21.59%
Gross Margin (Annual)71.92%
Net Profit Margin (5Y Avg)26.98%
Cash / Share (Quarterly)$4.62
P/E Basic Excl Extra (TTM)12.31x
Revenue Growth QoQ (YoY)1.89%
EPS Growth (5Y)11.97%
P/E Normalized (Annual)12.17x
ROA (Last FY)17.28%
Revenue Growth TTM (YoY)2.40%
EBITD / Share (TTM)$7.85
ROE (5Y Avg)54.42%
Operating Margin (TTM)34.79%
Cash Flow / Share (Annual)$5.37
P/B Ratio10.06x
P/B Ratio (Quarterly)15.38x
Net Income / Employee (Annual)$184,300
EV / Revenue (TTM)4.17x
Net Interest Coverage (TTM)15.44x
ROA (TTM)17.54%
EPS Growth QoQ (YoY)1.02%
EV / EBITDA (TTM)11.54x
EPS Incl Extra (Annual)$6.02
Current Ratio (Annual)3.03x
Quick Ratio (Quarterly)1.91x
3-Month Avg Trading Volume5.51M
52-Week Price Return-52.89%
EV / Free Cash Flow (Annual)17.36x
P/E Incl Extra (TTM)12.31x
Revenue / Employee (TTM)$655,800
Tangible BV / Share (Quarterly)$5.41
P/S Ratio (Annual)3.44x
Asset Turnover (Annual)0.61x
52-Week High$171.52
Operating Margin (5Y Avg)33.71%
EPS Excl Extra (Annual)$6.02
CapEx CAGR (5Y)6.51%
Tangible BV CAGR (5Y)2.53%
26-Week Price Return-38.02%
Quick Ratio (Annual)1.94x
13-Week Price Return-35.01%
Total Debt / Equity (Annual)2.72x
Current Ratio (Quarterly)3.15x
Enterprise Value$39.63B
Revenue / Share Growth (5Y)8.87%
Asset Turnover (TTM)0.63x
Book Value / Share Growth (5Y)-0.24%
Revenue / Employee (Annual)$652,900
Inventory Turnover (Annual)1.12x
Pretax Margin (Annual)35.49%
Cash / Share (Annual)$5.44
3-Month Return Std Dev52.67%
Gross Margin (5Y Avg)70.68%
Net Income / Employee (TTM)$182,300
EBITDA CAGR (5Y)10.10%
EBITDA Interim CAGR (5Y)1.65%
ROE (Last FY)80.25%
Net Interest Coverage (Annual)12.66x
EPS Basic Excl Extra (Annual)$6.02
P/FCF (TTM)15.23x
Receivables Turnover (TTM)6.63x
EV / Free Cash Flow (TTM)18.55x
Total Debt / Equity (Quarterly)2.80x
EPS Incl Extra (TTM)$6.04
Receivables Turnover (Annual)6.52x
ROI (TTM)21.72%
Dividend Growth Rate (5Y)20.56%
P/S Ratio (TTM)3.42x
Pretax Margin (5Y Avg)33.71%
Revenue / Share (Annual)$21.33
Tangible BV / Share (Annual)$5.49
Forward P/E10.96x
Free OCF CAGR (5Y)6.41%
Price vs S&P 500 (52W)-77.25%
P/E Ratio (TTM)12.31x
EPS Growth TTM (YoY)8.39%
Year-to-Date Return-36.86%
5-Day Price Return2.42%
EPS Normalized (Annual)$6.02
ROA (5Y Avg)15.99%
Net Profit Margin (Annual)28.23%
Month-to-Date Return2.25%
Cash Flow / Share (TTM)$5.96
EBITD / Share (Annual)$7.86
EPS Growth (3Y)10.25%
Operating Margin (Annual)35.49%
LT Debt / Equity (Annual)2.71x
P/CF (TTM)11.97x
ROI (5Y Avg)19.84%
P/E Excl Extra (TTM)12.31x
LT Debt / Equity (Quarterly)2.80x
EPS Basic Excl Extra (TTM)$6.04
P/TBV (Quarterly)21.86x
Payout Ratio (Annual)33.26%
P/B Ratio (Annual)16.65x
Dividend / Share (TTM)$2.05
Inventory Turnover (TTM)1.09x
Pretax Margin (TTM)34.79%
Book Value / Share (Annual)$7.84
Price vs S&P 500 (13W)-43.26%
Net Margin Growth (5Y)2.84%
Dividend Yield (TTM)2.73%
Beta0.72x
P/FCF (Annual)14.25x
Revenue / Share (TTM)$22.51
ROE (TTM)62.41%
52-Week Low$72.38
vGradeC
gGradeC
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 261.53est. 1.63
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.88
3.84
3.92
3.83
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ZTSZOETIS INC. | C | C | D | $79.44 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Zoetis is the global leader in animal health, offering vaccines, diagnostics, parasiticides, and anti-infectives for both companion and production animals. The company generates approximately 65% of revenue from companion animal products (dogs, cats, horses) and 35% from production animal health (cattle, pigs, poultry), with domestic operations tilted toward companion animals and international operations toward production animals. Spun from Pfizer's animal health unit, Zoetis holds the largest market share in the industry.